1. BEGIN File 72 to search EMBASE.

2. SELECT brand names limiting to the Brand Name (/TN) field.

Be sure to enclose the ANDed terms in parentheses so they both will be searched in the /TN field.

?b 72

       File  72:EMBASE 1993-2007/Mar 21
       (c) 2007 Elsevier B.V.
      Set  Items  Description
      ---  -----  -----------
?s (synercid and  rocephin)/tn
             438  SYNERCID/TN
             729  ROCEPHIN/TN
      S1      17  (SYNERCID AND ROCEPHIN)/TN

3. TYPE a few records using the Title (TI), Brand Name (TN), Manufacturer Name (MN) and Descriptor (DE) fields.

Note: Parts of the records are omitted from this display.

?t s1/ti,tn,mn,de/1-3

  1/TI,TN,MN,DE/1 
  DIALOG(R)File 72: EMBASE
  (c) 2007 Elsevier B.V. All rights reserved.

Abbreviated guidelines for prevention, diagnostics, and therapy  
of nosocomial pneumonia 


  AKTUALISIERTE KURZFASSUNG DER LEITLINIEN ZUR PRAVENTION, 
DIAGNOSTIK UND  THERAPIE DER NOSOKOMIAL ERWORBENEN PNEUMONIE 
  Brand Name/Manufacturer Name: augmentan; unacid; pipril; baypen;  
tazobac; staphylex; zinacef; spizef; claforan; rocephin; fortum; 
maxipime;  cefrom; zienam; meronem; tarivid; ciprobay; tavanic; 
avalox; biklin; refobacin;  certomycin; gernebcin; erythrocin; 
klacid; sobelin; targocid; synercid;  eremfat; rifa; zyvoxid; 
fosfocin; vancomycin 
  DRUG DESCRIPTORS: 
  penicillin G--drug therapy--dt; cephalosporin--drug 
combination--cb;  cephalosporin--drug therapy--dt; antiinfective 
agent--drug combination--cb; antiinfective  agent--drug 
therapy--dt; carbapenem--drug combination--cb; carbapenem--drug  
therapy--dt; 
.... 
  MEDICAL DESCRIPTORS: 
  * hospital infection--diagnosis--di; *hospital infection--drug 
therapy--dt; *  hospital infection--etiology--et; *hospital 
infection--prevention--pc; *  pneumonia--diagnosis--di; 
*pneumonia--drug therapy--dt; *pneumonia --prevention--pc 
  practice guideline; disease severity; concept formation; 
Germany; clinical  pathway; health care; medical documentation; 
human; review 

  1/TI,TN,MN,DE/2 
  DIALOG(R)File 72: EMBASE
  (c) 2007 Elsevier B.V. All rights reserved.
  
  The historical delivery of antibiotics from microbial natural 
products - Can  history repeat? 
  
  Brand Name/Manufacturer Name: mefoxin; ceclor; claforan; 
rocephin;  ceftin; primaxin; invanz; erythrocin; biaxin; ketek; 
vancocin; monuril;  bactroban; fusidin; cubicin; zithromax; 
synercid 
  DRUG DESCRIPTORS: 
  * antibiotic agent--drug development--dv 
  penicillin G--drug development--dv; cephalosporin 
derivative--drug  development--dv; thienamycin--drug 
development--dv; erythromycin--drug  development--dv; 
vancomycin--drug development--dv; fosfomycin--drug  
development--dv; pseudomonic acid--drug development--dv; 
fusidic acid--drug  development--dv;  ....
  MEDICAL DESCRIPTORS: 
  drug industry; drug synthesis; drug research; microbial 
diversity; drug  screening; drug isolation; drug identification; 
high throughput screening; drug  structure; review; priority 
journal 
  
  1/TI,TN,MN,DE/3
  DIALOG(R)File 72: EMBASE
  (c) 2007 Elsevier B.V. All rights reserved.
  
  Wildcatters welcome: The need for new antimicrobial agents 
  
  Brand Name/Manufacturer Name: synercid/Aventis; zyvox/Pharmacia;
cubicin/Chiron; rocephin/Hoffmann La Roche;  ketek/Aventis; 
arestin/Orapharm 
  Manufacturer Names: Aventis; Pharmacia; Chiron; Hoffmann La 
Roche; Orapharm 
  DRUG DESCRIPTORS: 
  * antiinfective agent 
  penicillin G; smallpox vaccine; poliomyelitis vaccine; 
vancomycin--drug  comparison--cm; meticillin; cephalosporin; 
ampicillin; natural product;  dalfopristin plus quinupristin--...
.MEDICAL DESCRIPTORS: 
drug design; drug industry; penicillin resistance; antibiotic 
resistance; Gram  positive bacterium; methicillin resistant 
Staphylococcus aureus; vancomycin  resistant Enterococcus; 
Staphylococcus aureus; Gram negative bacterium;  Escherichia 
coli; Klebsiella pneumoniae; Pseudomonas aeruginosa; Acinetobacter  
baumannii; economic aspect; antimicrobial activity; point mutation; 
bacterial  genome; drug targeting; phlebitis--side effect--si; 
arthralgia--side  effect--si; myalgia--side effect--si; 
thrombocytopenia --side effect--si;  muscle injury--side 
effect--si; drug half life; health care system; human;  
clinical trial; editorial